Masanaga Muto

Dr. Masanaga Muto


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Viruses
Verified
Journal Article
Open access
PDF file
BJBat-Erdene Jargalsaikhan
Bat-Erdene Jargalsaikhan
MMMasanaga Muto
Masanaga Muto
YBYoungeun Been
Youngeun Been
SMShoma Matsumoto
Shoma Matsumoto
EOEiichi Okamura
Eiichi Okamura
MEMasatsugu Ema
Masatsugu Ema
A gene delivery system utilizing lentiviral vectors (LVs) requires high transduction efficiency for successful application in human gene therapy. Pseudotyping allows viral tropism to be expanded, widening the usage of LVs. While vesicular stomatitis virus G (VSV-G) single-pseudotyped LVs are commonly used, dual-pseudotyping is less frequently employed because of its increased complexity. In this study, we examined the potential of phenotypically mixed heterologous dual-pseudotyped LVs with VSV-G and Sendai virus hemagglutinin-neuraminidase (SeV-HN) glycoproteins, termed V/HN-LV. Our findings demonstrated the significantly improved transduction efficiency of V/HN-LV in various cell lines of mice, cynomolgus monkeys, and humans compared with LV pseudotyped with VSV-G alone. Notably, V/HN-LV showed higher transduction efficiency in human cells, including hematopoietic stem cells. The efficient incorporation of wild-type SeV-HN into V/HN-LV depended on VSV-G. SeV-HN removed sialic acid from VSV-G, and the desialylation of VSV-G increased V/HN-LV infectivity. Furthermore, V/HN-LV acquired the ability to recognize sialic acid, particularly N-acetylneuraminic acid on the host cell, enhancing LV infectivity. Overall, VSV-G and SeV-HN synergistically improve LV transduction efficiency and broaden its tropism, indicating their potential use in gene delivery.

24 July 2025 in Viruses
Verified
Journal Article
Open access
PDF file
BJBat-Erdene Jargalsaikhan
Bat-Erdene Jargalsaikhan
MMMasanaga Muto
Masanaga Muto
MEMasatsugu Ema
Masatsugu Ema
Over 35 years of history, the field of gene therapy has undergone much progress. The initial concept—the replacement of dysfunctional genes with correct ones—has advanced to the next stage and reached the level of precise genome editing. Dozens of gene therapy products based on viral and non-viral delivery platforms have been approved, marking the dawn of the gene therapy era. These viral vector strategies rely on adenoviruses, adeno-associated viruses, lentivirus-derived tools, and so on. From the middle of the gene therapy transition, despite the challenges and serious negative consequences, the lentiviral vector has emerged as a cornerstone and demonstrated benefits in fields ranging from basic science to gene therapy. Therefore, we outline the importance of lentiviral vectors in the gene therapy era by focusing on their roles in the clinical usage, derivation, and development of next-generation platforms, as well as their pseudotyping.

12 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BJBat-Erdene Jargalsaikhan
Bat-Erdene Jargalsaikhan
MMMasanaga Muto
Masanaga Muto
MEMasatsugu Ema
Masatsugu Ema
Over 35 years of history, the field of gene therapy has undergone much progress. The initial concept, the replacement of dysfunctional genes with the correct ones, was advanced to the next stages and reached the level of precise genome editing. Dozens of gene therapy products based on viral and non-viral delivery platforms have been approved, marking the dawn of the gene therapy era. These viral vector strategies rely on adenoviruses, adeno-associated viruses, lentivirus-derived tools, and so on. From the middle of the gene therapy transition, despite the challenges and serious negative consequences, the lentiviral vector has emerged as a cornerstone and demonstrated its benefits from basic science to gene therapy. Therefore, we outlined the importance of lentiviral vectors in the gene therapy era by focusing on the role of the lentiviral vectors in clinical usage, derivation, and development of the next-generation platforms, as well as pseudotyping.